Thorsen Group Invests in Airofit

Airofit specializes in respiratory training, combining evidence-based exercises with user-friendly technology to improve lung function, physical performance, and overall quality of life.

The company has developed the world’s first app-controlled breathing trainer with integrated sensor technology, allowing users to measure and improve their lung function, respiratory strength, and capacity – regardless of age, fitness level, or health condition.

Airofit offers a fully digital, user-friendly, and documented solution to one of today’s most overlooked yet crucial health factors: breathing. In a world marked by rising cases of respiratory diseases, long-term effects of COVID-19, increased stress levels, and declining physical activity, Airofit addresses a growing global health challenge with a solution that is both accessible and evidence-based.

“We see great potential in Airofit’s mission to improve people’s quality of life through innovative breathing technology. Their strong combination of medical application and performance optimization aligns perfectly with our strategy of supporting companies with global ambitions and technological lead,” says Lars Frøvang Thomsen, CEO of Thorsen Group.

The investment will support the international launch of Airofit Medical – a digital respiratory trainer targeted at patients with chronic lung conditions such as COPD, asthma, sleep apnea, and late effects after COVID-19. Additionally, the investment will contribute to further strengthening and developing Airofit Pro 2.0, which is already used by elite athletes and sports professionals around the world.

“Airofit is at a critical juncture, and with Thorsen Group behind us, we now have the right resources to bring our solutions to even more people globally,” says Christian Tullberg Poulsen, CEO of Airofit.